Salspera (TKVA.US) Sets IPO Price Range at $14-$16 Per Share, Aiming for $85 Million Raise

Stock News15:06

Clinical-stage cancer biotechnology firm Salspera (TKVA.US), which focuses on developing live biotherapeutic products to stimulate immune responses, announced the terms for its U.S. initial public offering (IPO) on Monday. The Cambridge, Massachusetts-based company intends to raise $85 million by offering 5.7 million shares within a price range of $14 to $16 per share. Salspera is dedicated to creating a novel class of immunotherapies for solid tumors, termed "live biotherapeutics," which are genetically modified biological agents designed to express specific anti-tumor factors within the tumor microenvironment. Its lead candidate, Saltikva, is an attenuated strain of Salmonella Typhimurium that is non-toxic and administered orally. This engineered strain is designed to express the human interleukin-2 gene (referred to as Salmonella-IL2), a mechanism that may help increase the population of NK cells and CD8+ cytotoxic T cells in both the tumor microenvironment and peripheral blood. The company's current primary focus is on pancreatic cancer, and it has completed a Phase II trial involving patients with Stage IV metastatic pancreatic cancer. Founded in 2017, Salspera plans to list on the Nasdaq exchange under the ticker symbol TKVA. Kingswood Capital Markets is acting as the sole book-running manager for the offering.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178888548?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 15:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178888548","market":"sh","top_or_hot":-1,"title":"Salspera (TKVA.US) Sets IPO Price Range at $14-$16 Per Share, Aiming for $85 Million Raise","media":"Stock News","content":"<p>Clinical-stage cancer biotechnology firm Salspera (TKVA.US), which focuses on developing live biotherapeutic products to stimulate immune responses, announced the terms for its U.S. initial public offering (IPO) on Monday. The Cambridge, Massachusetts-based company intends to raise $85 million by offering 5.7 million shares within a price range of $14 to $16 per share. Salspera is dedicated to creating a novel class of immunotherapies for solid tumors, termed \"live biotherapeutics,\" which are genetically modified biological agents designed to express specific anti-tumor factors within the tumor microenvironment. Its lead candidate, Saltikva, is an attenuated strain of Salmonella Typhimurium that is non-toxic and administered orally. This engineered strain is designed to express the human interleukin-2 gene (referred to as Salmonella-IL2), a mechanism that may help increase the population of NK cells and CD8+ cytotoxic T cells in both the tumor microenvironment and peripheral blood. The company's current primary focus is on pancreatic cancer, and it has completed a Phase II trial involving patients with Stage IV metastatic pancreatic cancer. Founded in 2017, Salspera plans to list on the Nasdaq exchange under the ticker symbol TKVA. Kingswood Capital Markets is acting as the sole book-running manager for the offering.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Salspera (TKVA.US) Sets IPO Price Range at $14-$16 Per Share, Aiming for $85 Million Raise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSalspera (TKVA.US) Sets IPO Price Range at $14-$16 Per Share, Aiming for $85 Million Raise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-24 15:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Clinical-stage cancer biotechnology firm Salspera (TKVA.US), which focuses on developing live biotherapeutic products to stimulate immune responses, announced the terms for its U.S. initial public offering (IPO) on Monday. The Cambridge, Massachusetts-based company intends to raise $85 million by offering 5.7 million shares within a price range of $14 to $16 per share. Salspera is dedicated to creating a novel class of immunotherapies for solid tumors, termed \"live biotherapeutics,\" which are genetically modified biological agents designed to express specific anti-tumor factors within the tumor microenvironment. Its lead candidate, Saltikva, is an attenuated strain of Salmonella Typhimurium that is non-toxic and administered orally. This engineered strain is designed to express the human interleukin-2 gene (referred to as Salmonella-IL2), a mechanism that may help increase the population of NK cells and CD8+ cytotoxic T cells in both the tumor microenvironment and peripheral blood. The company's current primary focus is on pancreatic cancer, and it has completed a Phase II trial involving patients with Stage IV metastatic pancreatic cancer. Founded in 2017, Salspera plans to list on the Nasdaq exchange under the ticker symbol TKVA. Kingswood Capital Markets is acting as the sole book-running manager for the offering.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FT_SY_MNQ","symbol_name":"微型NQ100指数","start_time":0,"source_url":"","article_id":"1178888548","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178888548","pubTimestamp":1771916786,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Clinical-stage cancer biotechnology firm Salspera (TKVA.US), which focuses on developing live biotherapeutic products to stimulate immune responses, announced the terms for its U.S. initial public...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"UWM":"罗素2000指数ETF两倍做多","BK4535":"淡马锡持仓","BK4581":"高盛持仓","TWM":"罗素2000指数两倍做空ETF","TZA":"罗素2000指数三倍做空ETF","IWO":"罗素2000成长股指数ETF","RWM":"罗素2000指数反向ETF","IWN":"罗素2000价值股指数ETF-iShares","TNA":"罗素2000指数三倍做多ETF-Direxion","BK4588":"碎股","BK4550":"红杉资本持仓","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","SRTY":"罗素2000指数三倍做空ETF-ProShares"},"translate_title":"Salspera(TKVA.US)将IPO价格区间定为每股14-16美元，目标融资8500万美元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNQmain":1,"TNA":1,"TZA":1,"IWN":1,"RWM":1,"TKVA":1,"UWM":1,"SRTY":1,"TWM":1,"IWO":1},"content_text":"Clinical-stage cancer biotechnology firm Salspera (TKVA.US), which focuses on developing live biotherapeutic products to stimulate immune responses, announced the terms for its U.S. initial public offering (IPO) on Monday. The Cambridge, Massachusetts-based company intends to raise $85 million by offering 5.7 million shares within a price range of $14 to $16 per share. Salspera is dedicated to creating a novel class of immunotherapies for solid tumors, termed \"live biotherapeutics,\" which are genetically modified biological agents designed to express specific anti-tumor factors within the tumor microenvironment. Its lead candidate, Saltikva, is an attenuated strain of Salmonella Typhimurium that is non-toxic and administered orally. This engineered strain is designed to express the human interleukin-2 gene (referred to as Salmonella-IL2), a mechanism that may help increase the population of NK cells and CD8+ cytotoxic T cells in both the tumor microenvironment and peripheral blood. The company's current primary focus is on pancreatic cancer, and it has completed a Phase II trial involving patients with Stage IV metastatic pancreatic cancer. Founded in 2017, Salspera plans to list on the Nasdaq exchange under the ticker symbol TKVA. Kingswood Capital Markets is acting as the sole book-running manager for the offering.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178888548","isCrawlerRequest":true}